EUVIMEDEUVIMED entdecken
Crossref

Synthesis of BI 1584142 and BI 1810631 (Zongertinib), Two Potent HER2 Inhibitors, Labeled With Carbon‐14 and With Deuterium

Bachir Latli iD, Eugene Chong

Journal of Labelled Compounds and Radiopharmaceuticals · 2025

DOI: 10.1002/jlcr.4168 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, 2025. Verfasst von Bachir Latli und 1 weiteren Autor:innen. Beteiligte Einrichtung: The Radiosynthesis Laboratory, Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA. Hauptthemen laut MEDLINE: Deuterium, Erb-b2 Receptor Tyrosine Kinases, Carbon Radioisotopes, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BI 1584142 (1) and BI 1810631 (2, zongertinib) are potent and selective HER2 tyrosine kinase inhibitors being developed for the treatment of non–small cell lung cancer. Carbon‐14–labeled versions of these drug candidates were needed to study their absorption, distribution, metabolism, and excretion in animals and in humans. BI 1584142 and BI 1810631 differ in two moieties; the former contains a piperazine and the latter a 4‐aminopiperidine. Therefore, a common carbon‐14–labeled intermediate like the sulfoxide [ 14 C]‐8 was prepared in four radioactive steps and used to provide [ 14 C]‐1 and [ 14 C]‐2 in two and three extra steps, respectively. Deuterium‐labeled 1 and 2 were also synthesized as internal standards, using piperazine‐ d 8 and 4‐aminopiperidine‐ d 9 for bioanalytical studies and other studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeuteriumErb-b2 Receptor Tyrosine KinasesCarbon RadioisotopesProtein Kinase InhibitorsIsotope LabelingChemistry Techniques, SyntheticHumans

Stichwörter der Autor:innen

BI 1584142BI 1810631HER2NSCLCcarbon‐14deuteriumzongertinib

Substanzen

DeuteriumErb-b2 Receptor Tyrosine KinasesCarbon RadioisotopesProtein Kinase InhibitorsCarbon-14

Autor:innen und Institutionen

  • The Radiosynthesis Laboratory, Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA.

ORCID-Profile: Bachir Latli

Zitieren

APA

Latli, B., & Chong, E. (2025). Synthesis of BI 1584142 and BI 1810631 (Zongertinib), Two Potent HER2 Inhibitors, Labeled With Carbon‐14 and With Deuterium. Journal of Labelled Compounds and Radiopharmaceuticals. https://doi.org/10.1002/jlcr.4168

Vancouver

Latli B, Chong E. Synthesis of BI 1584142 and BI 1810631 (Zongertinib), Two Potent HER2 Inhibitors, Labeled With Carbon‐14 and With Deuterium. Journal of Labelled Compounds and Radiopharmaceuticals. 2025. doi:10.1002/jlcr.4168

BibTeX
@article{Latli2025,
  author = {Latli, Bachir and Chong, Eugene},
  title = {Synthesis of BI 1584142 and BI 1810631 (Zongertinib), Two Potent HER2 Inhibitors, Labeled With Carbon‐14 and With Deuterium},
  journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
  year = {2025},
  doi = {10.1002/jlcr.4168}
}
Kostenlos starten →